CD28 and congenital rubella syndrome: Since 4-1BB containing CAR-Ts generate clinical responses but with lower cytokine release syndrome (CRS) risk, and potentially longer persistence than CD28 containing CAR-T products, we wanted to confirm our prediction that a 4-1BB-only containing Luc90-CAR-T would a retain high anti-tumor activity.